ArticleCancer cell international2025
Hsa_circ_0059511 promote glioma cell proliferation and migration through hsa-miR-194-5p/HBEGF axis.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Upregulated CircRNAs With Efficacy in PreclinicalCancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A growing number of studies have highlighted the critical role that circular RNAs play in cancer. We previously observed that hsa_circ_0059511 was markedly upregulated in glioma tissues, suggesting that it may play an oncogenic role in gliomas. But its mechanism is not clear. The aim of the present study was to investigate the biological function of hsa_circ_0059511 in gliomas. First, the expression levels of heparin-binding EGF-like growth factor (HBEGF), hsa_circ_0059511, and hsa-miR-194-5p in glioma tissues and cells were measured by qRT-PCR. Furthermore, cell viability, migration, and invasion were evaluated in vitro using CCK8 assay, EdU assay, and Transwell invasion assay after pcNDA-hsa_circ_0059511 transfection to increase hsa_circ_0059511 and siRNA transfection to suppress hsa_circ_0059511 in glioma cells. Finally, RNA immunoprecipitation (RIP) and a dual-luciferase reporter assay were used to determine the association between hsa-miR-194-5p and hsa_circ_0059511 or HBEGF. Our results showed that the expression levels of hsa_circ_0059511 were significantly increased in glioma tissues and cells compared to the control group (all p < 0.05). Furthermore, cell proliferation and invasion in vitro were restricted by knockdown of hsa_circ_0059511. Of note, we found that downregulation of hsa-miR-194-5p, a target microRNA of hsa_circ_0059511, could reverse the reduction in glioma cell proliferation and migration caused by silencing of hsa_circ_0059511. At the same time, we also found that hsa-miR-194-5p could suppress the proliferation and migration of glioma cells by inhibiting the expression of HBEGF, a target gene of hsa-miR-194-5p. Overall, our results showed that hsa_circ_0059511 increased HBEGF expression by sponging hsa-miR-194-5p to promote tumor cell migration and proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.